Monoclonal antibodies used for the management of hemataological disorders

References

• Chiu ML, Goulet DR, Teplyakov A, et al. Antibody structure and function: the basis for engineering therapeutics. Antibodies (Basel). 2019;855:1–80.
   Google Scholar
• Leung D, Wurst JM, Liu T, et al., Antibody Conjugates-Recent advances and future innovations. Antibodies. 2020;9; 2:1–27.
   Google Scholar
• Ghosh K. Advances in treatment of hematological disorders. Indian J Hematol Blood Transfus. 1987;5:87–94.
   Google Scholar
• Ghosh K, Ghosh K. Advances in haematological pharmacotherapy in 21st century. Indian J Hematol Blood Transfus. 2010;26:30–40.
   PubMedGoogle Scholar
• Salles G, Barrett M, Foà R, et al. DG. rituximab in B-Cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34:2232–2273.
   PubMed Web of Science ®Google Scholar
• R-M L, Y-C H, Liu I- J I-J, et al., Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1). https://doi.org/10.1186/s12929-019-0592-z1-30
   Google Scholar
• Thomas A, Teicher BA, Hassan R. Antibody–drug conjugates for cancer therapy. Lancet Oncol. 2016;17(6):e254–e262.
   PubMed Web of Science ®Google Scholar
• Palanca-Wessels MC, Press OW. Advances in the treatment of hematologic malignancies using immunoconjugates. Blood. 2014;123:2293–2301.
   PubMed Web of Science ®Google Scholar
• Saeed AFUH, Wang R, Ling S, et al. Antibody engineering for pursuing a healthier future. Front Microbiol. 2017;8(495):1–20.
   PubMedGoogle Scholar
• Kang HN, Thorpe R, Knezevic I, etal., Survey participants from 19 countries. The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019. Biologicals. 2020;65:1–9.
   PubMed Web of Science ®Google Scholar
• Jurczak W, Długosz Danecka M, Buske C, et al. Rituximab biosimilars for lymphoma in Europe. Expert Opin Biol Ther. 2019;19:1045–1056.
   PubMed Web of Science ®Google Scholar
• Ganesan P, Sagar TG, Kannan K, et al. Long-term outcome of diffuse large B-cell lymphoma: impact of biosimilar rituximab and radiation. Indian J Cancer. 2017;54:430–435.
   PubMed Web of Science ®Google Scholar
• Pavlasova G, Mraz M. The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy. Haematologica. 2020;105:1494–1506.
   PubMed Web of Science ®Google Scholar
• Juárez-Salcedo LM, Conde-Royo D, Quiroz-Cervantes K, et al. Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature. Drugs Context. 2020;29:2019–2030.
   Google Scholar
• Kesavan M, Eyre TA, Collins GP. Front-Line treatment of high grade b cell Non-Hodgkin lymphoma. Curr Hematol Malig Rep. 2019;14:207–218.
   PubMedGoogle Scholar
• Flowers CR, Leonard JP, Fowler NH. Lenalidomide in follicular lymphoma. Blood. 2020;135:2133–2136.
   PubMed Web of Science ®Google Scholar
• Stasi R, Pagano A, Stipa E, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98:952–957.
   PubMed Web of Science ®Google Scholar
• Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol. 2001;141:149–169.
   Google Scholar
• Solomon SR, Sizemore CA, Ridgeway M, et al. Safety and efficacy of rituximab-based first line treatment of chronic GVHD. Bone Marrow Transplant. 2019;54:1218–1226.
   PubMedGoogle Scholar
• Attias D, Weitzman S. The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence. Curr Opin Pediatr. 2008;20:17–22.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-Rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381:432.
   PubMed Web of Science ®Google Scholar
• Davies A, Berge C, Boehnke A, et al. Subcutaneous rituximab for the treatment of B-Cell hematologic malignancies: a review of the scientific rationale and clinical development. Adv Ther. 2017;34:2210–2231.
   PubMed Web of Science ®Google Scholar
• Kim BK, Kang HJ, Hong KT, et al. Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation. Transpl Infect Dis. 2019;21:e13182.
   PubMedGoogle Scholar
• Kasi PM, Tawbi HA, Oddis CV, et al. Clinical review: serious adverse events associated with the use of rituximab - a critical care perspective. Crit Care. 2012;16:231–242.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Rajkumar SV Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:548–567.
   PubMed Web of Science ®Google Scholar
• Daratumumab SYY. A review in combination therapy for transplant-Ineligible newly diagnosed multiple myeloma. Drugs. 2019;79:447–454.
   PubMedGoogle Scholar
• Jain A, Ramasamy K. Evolving role of daratumumab: from backbencher to frontline agent. Clin Lymphoma Myeloma Leuk. 2020 2;S2152-2650:30143–30149.
   Google Scholar
• Killock D. New daratumumab quadruplets and triplets for newly diagnosed MM. Nat Rev Clin Oncol. 2019;16:526–527.
   PubMed Web of Science ®Google Scholar
• Bruins WSC, Zweegman S, Mutis T, et al. Targeted therapy with immunoconjugates for multiple myeloma. Front Immunol. 2020;11:1155–1166.
   PubMed Web of Science ®Google Scholar
• Richter J, Sanchez L, Thibaud S. Therapeutic potential of isatuximab in the treatment of multiple myeloma: evidence to date. Semin Oncol. 2020;47:155–164.
   PubMedGoogle Scholar
• Franssen LE, Stege CAM, Zweegman S, et al. Resistance mechanisms towards CD38-Directed antibody therapy in multiple myeloma. J Clin Med. 2020;9:1195.
   Web of Science ®Google Scholar
• Ferreira LM, Cerezer JL, Gehrcke M. Do cytomegalovirus infections affect the daratumumab treatment course in multiple myeloma patients? - literature review. Hematol Transfus Cell Ther. 2020;S2531-1379:30083.
   Google Scholar
• Mateos MV, Nahi H, Legiec W, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020;7:e370–e380.
   PubMed Web of Science ®Google Scholar
• Schwotzer R, Manz MG, Pederiva S, et al. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden. Hematol Oncol. 2019;37:595–600.
   PubMed Web of Science ®Google Scholar
• Shigle TL. Bashir Q advancement in monoclonal antibody therapy for multiple myeloma. Lancet Haematol. 2020;7:e354–e355.
   PubMedGoogle Scholar
• Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207–221.
   PubMed Web of Science ®Google Scholar
• Musto P, La Rocca F. MoAb in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses. Expert Rev Hematol. 2020;13:331–349.
   PubMed Web of Science ®Google Scholar
• Choi Y, Diefenbach CS. An evaluation of brentuximab vedotin as a treatment option for stage III/IV Hodgkin lymphoma. Expert Rev Hematol. 2019;12:801–808.
   PubMedGoogle Scholar
• Shea L, Mehta-Shah N. Brentuximab vedotin in the treatment of peripheral t cell lymphoma and cutaneous t cell lymphoma. Curr Hematol Malig Rep. 2020;15:9–19.
   PubMedGoogle Scholar
• Moskowitz AJ. Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy. Hematology Am Soc Hematol Educ Program. 2018;30:207–212.
   Google Scholar
• Vu K, Ai W. Ai W update on the treatment of anaplastic large cell lymphoma. Curr Hematol Malig Rep. 2018;13:135–141.
   PubMedGoogle Scholar
• Estey E, Karp JE, Emadi A, et al. Gale RP recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a trojan horse? Leukemia. 2020;34:671–681.
   PubMed Web of Science ®Google Scholar
• Burnett A, Stone R. AML: new drugs but new challenges. Clin Lymphoma Myeloma Leuk. 2020;20:341–350.
   PubMed Web of Science ®Google Scholar
• Richard-CarpentierG D. Single-agent and combination biologics in acute myeloid leukemia. 2019;Am Soc Hematol Educ Program. 2019:548–556.
   PubMedGoogle Scholar
• Egan PC, Reagan JL. The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody–drug conjugate for the treatment of newly diagnosed acute myeloid leukemia onco targets ther. OncoTargets and Therapy. 2018;11:8265–8272.
   PubMed Web of Science ®Google Scholar
• Röth A, Araten DJ, Larratt L, et al. Beneficial effects of Eculizumab regardless of prior transfusions or bone marrow disease: results of the International PNH registry. Eur J Haematol. 2020;105(5):561–570.
   PubMedGoogle Scholar
• Raina R, Grewal MK, Radhakrishnan Y. Radhakrishnan Y et al.Optimal management of atypical hemolytic uremic disease: challenges and solutions. Int J Nephrol Renovasc Dis. 2019;12(12):183–204.
   PubMedGoogle Scholar
• GiglhuberK B, Berthele A. Eculizumab in the treatment of neuromyelitis optica spectrum disorder. Immunotherapy. 2020;12:1053–1066.
   PubMedGoogle Scholar
• Benamu E, Montoya JG. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis. 2016;29:319–329.
   PubMed Web of Science ®Google Scholar
• Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. 2017;Am J Hematol. 92:946–965.
   PubMed Web of Science ®Google Scholar
• Jiang L, Yuan CM, Hubacheck J, et al. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol. 2009;145:173–179.
   PubMed Web of Science ®Google Scholar
• PierriF D. Management of aplastic anaemia after failure of frontline immunosuppression. Expert Rev Hematol. 2019;12:809–819.
   PubMedGoogle Scholar
• Kanda J, Lopez RD, Rizzieri DA. Rizzieri DA. alemtuzumab for the prevention and treatment of graft-versus-host disease. Int J Hematol. 2011;93:586–593.
   PubMed Web of Science ®Google Scholar
• Parrondo RD, Sher T. Prevention of skeletal related events in multiple myelomac:focus on the rank-l pathway in the treatment of multiple myeloma. Onco Targets Ther. 2019;12:8467–8478.
   PubMed Web of Science ®Google Scholar
• Pazianas M. Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer Inst. 2011;103:232–240.
   PubMed Web of Science ®Google Scholar
• Okura N, Asano M, Uchino J, et al. Endocrinopathies associated with immune checkpoint inhibitor cancer treatment: a review. J Clin Med. 2020;9:E2033.
   PubMedGoogle Scholar
• Bekoz H, Ozbalak M, Karadurmus N, et al. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Ann Hematol. 99(11):2565–2576. 2020.
   PubMed Web of Science ®Google Scholar
• Hradska K, Kascak M, Hajek R, et al. Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma. Expert Rev Hematol. 13(13):375–392. 2020.
   PubMedGoogle Scholar
• Armand P, Lesokhin A, Borrello I, et al. A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies. Leukemia. 2021;35(3):777–786.
   PubMed Web of Science ®Google Scholar
• Jelinek T, Paiva B, Hajek R. Update on PD-1/PD-L1 inhibitors in multiple myeloma. Front Immunol. 2018;9:2431.
   PubMed Web of Science ®Google Scholar
• Badros AZ, Ma N, Rapoport AP, et al. Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma. Blood Adv. 2019;3:1658–1660.
   PubMed Web of Science ®Google Scholar
• Grimm SE, Fayter D, Ramaekers BLT, et al. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2019;37:1195–1207.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Knaus HA, Robinson TM, et al. A multi-center phase i trial of ipilimumab in patients with myelodysplastic syndromes following hypomethylating agent failure. Clin Cancer Res. 2018;24:3519–3527.
   PubMed Web of Science ®Google Scholar
• Christian BA, Poi M, Jones JA, et al. The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Br J Haematol. 2015;169:701–710.
   PubMedGoogle Scholar
• Robak P, Robak T. Management of multiple myeloma with second-Generation antibody-Drug conjugates. BioDrugs. 2016;30:87–93.
   PubMedGoogle Scholar
• Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29:2493–2498.
   PubMed Web of Science ®Google Scholar
• Ribera JM. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia. Expert Rev Hematol. 2017;10:1057–1067.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Sasaki K, Ravandi F, et al. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer. 2018;124:4044–4055.
   PubMed Web of Science ®Google Scholar
• Hoelzer D. Hoelzer D Targeted therapy with MoAb in acute lymphoblastic leukemia. Curr Opin Oncol. 2013;25:701–706.
   PubMedGoogle Scholar
• Camicia R, Winkler HC, Hassa PO. Hassa PO novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer. 2015;14:207–221.
   PubMed Web of Science ®Google Scholar
• Mavromatis BH, Cheson BD. Cheson BD novel therapies for chronic lymphocytic leukemia. Blood Rev. 2004;18:137–148.
   PubMed Web of Science ®Google Scholar
• Anastasia A, Rossi G. Novel drugs in follicular lymphoma. Mediterr J Hematol Infect Dis. 2016;8(1):e2016061.
   PubMedGoogle Scholar
• Kreitmanl RJ, Dearden C, Zinzani PL, et al. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. J Hematol Oncol. 2021;14(35):1–11.
   PubMedGoogle Scholar
• Robak T. Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art. Expert Rev Hematol. 2014;7(7):841–857.
   PubMedGoogle Scholar
• Awan FT, Hillmen P, Hellmann A, et al. (LUCID trial investigators). A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. Br J Haematol. 2014;167:466–477.
   PubMed Web of Science ®Google Scholar
• Liebers N, Duell J, Fitzgerald D, et al. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Adv. 2021;5:2707–2716.
   PubMed Web of Science ®Google Scholar
• Mestel DS, Beyer M, Möbs M, et al. Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome. Expert Opin Biol Ther. 2008;8:1929–1939.
   PubMed Web of Science ®Google Scholar
• Kim YH, Duvic M, Obitz E, et al. Clinical efficacy of zanolimumab(HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood. 2007;109:4655–4662.
   PubMed Web of Science ®Google Scholar
• Satake A, Konishi A, Azuma Y, et al. Clinical efficacy of mogamulizumab for relapsed/refractory aggressive adult T-cell leukemia/lymphoma: a retrospective analysis. Eur J Haematol. 2020;105(6):704–711.
   PubMedGoogle Scholar
• Lewis DJ, Rook AH. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy. Expert Rev Anticancer Ther. 2020;20:447–452.
   PubMed Web of Science ®Google Scholar
• Karathanos A, Lin Y, Dannenberg L, et al. Routine glycoprotein IIb/IIIa Inhibitor therapy in ST-Segment elevation myocardial infarction: a meta-analysis. Can J Cardiol. 2019;35:1576–1588.
   PubMed Web of Science ®Google Scholar
• Bachlava E, Loukopoulou S, Karanasios E, et al. Management of coronary artery aneurysms using Abciximab in children with Kawasaki disease. Int J Cardiol. 2016;220:65–69.
   PubMedGoogle Scholar
• Vázquez C, Gonzalez ML, Ferraris A, et al. Bevacizumab for treating hereditary hemorrhagic telangiectasia patients with severe hepatic involvement or refractory anemia. PLoS One. 2020;15:e0228486.
   PubMedGoogle Scholar
• Iyer VN, Apala DR, Pannu BS, et al. Intravenous bevacizumab for refractory hereditary hemorrhagic telangiectasia-Related epistaxis and gastrointestinal bleeding. Mayo Clin Proc. 2018;93:155–166.
   PubMedGoogle Scholar
• Ghosh K, Ghosh K. Hereditary haemorrhagic telangiectasia (HHT): negotiating between the Scylla of bleeding and Charybdis of thrombosis. Thromb Haemost. 2008;100:162–164.
   PubMedGoogle Scholar
• Sohail A, Mushtaq A, Iftikhar A, et al. Emerging immune targets for the treatment of multiple myeloma. Immunotherapy. 2018;10(10):265–282.
   PubMedGoogle Scholar
• Franchini M, Marano G, Pati I, et al. Investigational drugs to treat hemophilia. Expert Opin Investig Drugs. 2020;29:295–301.
   PubMed Web of Science ®Google Scholar
• Nogami K, Shima M. New therapies using nonfactor products for patients with hemophilia and inhibitors. Blood. 2019;133:399–406.
   PubMed Web of Science ®Google Scholar
• Gelbenegger G, Schoergenhofer C, Knoebl P, et al. Bridging the missing link with emicizumab: a bispecific antibody for treatment of hemophilia A. Thromb Haemost. 2020;120(10):1357–1370.
   PubMed Web of Science ®Google Scholar
• Knoebl P, Thaler J, Jilma P, et al. Emicizumab for the treatment of acquired hemophilia A. Blood. 2021;137(3):410–419.
   PubMed Web of Science ®Google Scholar
• Han J, Saraf SL, Gordeuk VR. Systematic review of crizanlizumab: a new parenteral option to reduce vaso-occlusive pain crises in patients with sickle cell disease. Pharmacotherapy. 2020;40:535–543.
   PubMed Web of Science ®Google Scholar
• Blair HA. Blair HA . crizanlizumab: first approval. Drugs. 2020;80:79–84.
   PubMed Web of Science ®Google Scholar
• Yalniz FF, Hefazi M, McCullough K, et al. Safety and efficacy of infliximab therapy in the setting of Steroid-Refractory acute graft-versus-Host disease. Biol Blood Marrow Transplant. 2017;23:1478–1484.
   PubMed Web of Science ®Google Scholar
• Henzan T, Nagafuji K, Tsukamoto H, et al. Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis. Am J Hematol. 2006;81(81):59–61.
   PubMedGoogle Scholar
• Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016;12:259–268.
   PubMed Web of Science ®Google Scholar
• Kotch C, Barrett D, Teachey DT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol. 2019;15:813–822.
   PubMed Web of Science ®Google Scholar
• Gergis U, van Besien K. Tocilizumab, in search for a role in acute GVHD. Leuk Lymphoma. 2019;60:2101–2103.
   PubMed Web of Science ®Google Scholar
• Jendoubi F, Gaudenzio N, Gallini A, et al. Omalizumab in the treatment of adult patients with mastocytosis: a systematic review. Clin Exp Allergy. 2020;50:654–661.
   PubMed Web of Science ®Google Scholar
• Harish A, Schwartz SA. Targeted Anti-IL-5 therapies and future therapeutics for hypereosinophilic syndrome and rare eosinophilic conditions. Clin Rev Allergy Immunol. 2020;59(2):231–247.
   PubMedGoogle Scholar
• Hanlon A, Metjian A. Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura. Ther Adv Hematol. 2020;11:204062072090290.
   Web of Science ®Google Scholar
• Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005;23(23):1126–1136.
   PubMedGoogle Scholar
• Ministro J, Manuel AM. Goncalves therapeutic antibody engineering and selection strategies. J Adv Biochem Eng Biotechnol. 2020;(171):55–86.
   PubMedGoogle Scholar
• Leung D, Wurst JMLiu T, et.al. Antibody conjugates-Recent advances and future innovations. Antibodies. 2020;9; 2:1–27.
   Google Scholar
• Weiner GJ. Monoclonal antibody mechanisms of action in cancer. Immunol Res. 2007;39(1–3):271–278.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Pfreundschuh M, Trneny M, et al. R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. Haematologica. 2014;99:1343–1349.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Greco FA, Raefsky EL, et al. Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2014;14:277–283.
   PubMedGoogle Scholar
• Hansel TT, Kropshofer H, Singer T, et al. The safety and side effects of MoAb. Nat Rev Drug Discov. 2010;9:325–338.
   PubMed Web of Science ®Google Scholar
• Sharman JP. Targeting CD20: teaching an old dog new tricks. Hematology Am Soc Hematol Educ Program. 2019;2019:273–278.
   PubMedGoogle Scholar
• Singh S, Kumar NK, Dwiwedi P, et al. MoAb: a Review. Curr Clin Pharmacol. 2018;13:85–99.
   PubMed Web of Science ®Google Scholar
• Thill M, Thatcher N, Hanes V, et al. Biosimilars: what the oncologist should know. Future Oncol. 2019;15:1147–1165.
   PubMedGoogle Scholar
• Orita T, Tsunoda H, Yabuta N, et al. A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. Blood. 2005;105:562–566.
   PubMed Web of Science ®Google Scholar
• Matsumura Y. Cancer stromal targeting (CAST) therapy. Adv Drug Deliv Rev. 2012;64:710–719.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Muralidharan M, Schneider Z, et al.Antibodies to watch in 2020.Mabs.2020;12(1):24; e1703531 ( pages
   Google Scholar